If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.475    0.145 (4.35%)
Bid:
3.315
Ask:
3.705
Spread: 0.39 (11.765%)
Market Cap: £21.68m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Total Voting Rights

16 Aug 2022 08:03

RNS Number : 0957W
Immupharma PLC
16 August 2022
 

RNS | 16 August 2022 

ImmuPharma plc

Total Voting Rights

ImmuPharma plc ("ImmuPharma" or "the Company"), announces that further to the announcements dated 3 August 2022 and 11 August 2022, the Subscription Shares, Placing Shares, Value Payment Shares, Fee Shares and Broker Option Shares (all as defined in the aforementioned announcements) have today been admitted to trading on AIM.

Consequently, the Company's issued share capital now comprises, 327,403,115 Ordinary Shares with one voting right each and 284,984,933 deferred shares with no rights to vote. As the Company does not hold any shares in treasury, the total number of voting rights in the Company is also 327,403,115 and this figure of Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

Ends

For further information, please contact:

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer & Chairman

+ 44 (0) 207 152 4080

Lisa Baderoon, Head of Investor Relations & Non-Executive Director

+ 44 (0) 7721 413496

 

 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

+44 (0) 203 368 3550

 

 

+44 20 3650 3650

 

 

+44 (0) 1483 413500

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TVRSFIESIEESEEA
Date   Source Headline
6th Oct 20225:17 pmRNSHolding(s) in Company
30th Sep 20227:30 amRNSLupuzor Update
30th Sep 20227:00 amRNSInterim Results or the 6mths Ended 30 June 2022
29th Sep 20224:40 pmRNSSecond Price Monitoring Extn
29th Sep 20224:37 pmRNSPrice Monitoring Extension
14th Sep 202210:04 amRNSWritten Response received from the FDA
7th Sep 20228:25 amRNSExercise of Options
31st Aug 20227:00 amRNSFDA response for Type C Meeting - update
30th Aug 202211:29 amRNSExercise of Options
24th Aug 20228:11 amRNSExercise of Options
17th Aug 20226:12 pmRNSTR-1 Notification of major holdings
16th Aug 20228:03 amRNSTotal Voting Rights
11th Aug 20227:00 amRNSResult of Broker Option / PDMR Dealings
4th Aug 20227:00 amRNSInvestor Presentation - Investor Meet Company
3rd Aug 20224:40 pmRNSSecond Price Monitoring Extn
3rd Aug 20224:35 pmRNSPrice Monitoring Extension
3rd Aug 20224:33 pmRNSSubscription/Placing to raise £1.1m; Broker Option
26th Jul 20224:41 pmRNSSecond Price Monitoring Extn
26th Jul 20224:35 pmRNSPrice Monitoring Extension
11th Jul 20227:00 amRNSInitiation of Research
7th Jul 20227:00 amRNSConfirmed FDA response date for Type C Meeting
28th Jun 20225:44 pmRNSAdmission of new ordinary shares of £0.01
28th Jun 202211:42 amRNSResult of AGM
27th Jun 20227:00 amRNSUpdate on Lupuzor
20th Jun 20223:22 pmRNSHolding(s) in Company
1st Jun 20227:00 amRNSNotice of AGM & Annual Report & Accounts
25th May 20227:00 amRNSFinals results for y/e 31 December 2021
4th May 20227:00 amRNSUPDATE on LUPUZOR™ PROGRESS to PHASE 3 with AVION
13th Apr 20227:00 amRNSUPDATE on P140 (LUPUZOR™) clinical progress
7th Feb 20227:00 amRNSLUPUZOR UPDATE
10th Jan 20227:00 amRNSTR-1: Notification of major holdings
5th Jan 20229:53 amRNSTR-1: Notification of major holdings
24th Dec 20218:34 amRNSHolding(s) in Company
20th Dec 20217:00 amRNSSubscriptions and Placing to raise £3.55 million
15th Dec 20214:35 pmRNSPrice Monitoring Extension
7th Dec 20214:41 pmRNSSecond Price Monitoring Extn
7th Dec 20214:36 pmRNSPrice Monitoring Extension
29th Nov 20217:00 amRNSCOLLABORATION WITH IMPERIAL COLLEGE LONDON
18th Nov 20217:00 amRNSCorporate Update
8th Nov 20214:41 pmRNSSecond Price Monitoring Extn
8th Nov 20214:36 pmRNSPrice Monitoring Extension
11th Oct 20214:35 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSEuronext Delisting
30th Sep 20217:15 amRNSPROF. SYLVIANE MULLER AWARDED ‘LEGION D’HONNEUR’
29th Sep 20217:30 amRNSInterim Results for the 6months ended 30 June 2021
29th Sep 20217:00 amRNSCorporate Update
22nd Sep 20214:36 pmRNSPrice Monitoring Extension
24th Aug 202111:07 amRNSDirector/PDMR Shareholding
20th Aug 20214:40 pmRNSSecond Price Monitoring Extn
20th Aug 20214:35 pmRNSPrice Monitoring Extension

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.